Videos

Conference Coverage

Consideration of Long Course Radiation for Patients With Rectal Cancer

05/21/2024

Jennifer Wo, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Jennifer Wo, MD, discussed use of long course neoadjuvant radiation therapy for the treatment of patients with rectal cancer.

At Great Debates and Updates in...

05/21/2024

Oncology

Author Interview

Virtual Reality to Predict Paravalvular Leak in Severe Bicuspid Aortic Valve Stenosis in Transcatheter Aortic Valve Implants: An Interview With Sergey Gurevich, MD

05/20/2024

Sergey Gurevich, MD

Dr Sergey Gurevich shares background and insights on his paper, "Virtual Reality to Predict Paravalvular Leak in Severe Bicuspid Aortic Valve Stenosis in Transcatheter Aortic Valve Implants."

Dr Sergey Gurevich shares...

05/20/2024

Journal of Invasive Cardiology

Videos

Pediatric Pilocytic Astrocytoma With a KIAA1549:BRAF Fusion

05/20/2024

Shubin Shahab, MD, PhD

Shubin Shahab, MD, PhD, discusses how to treat a patient with pediatric pilocytic astrocytoma with a KIAA1549:BRAF fusion.

Shubin Shahab, MD, PhD,...

05/20/2024

Oncology

Clinical Videos

Successful Valve-in-Valve Replacement Using Intravascular Lithotripsy for Femoral Access in an Elderly Patient With Critical Aortic Stenosis and Extensive Vascular Calcification

05/20/2024

Borja Rivero-Santana, MD; Guillermo Galeote, MD, PhD; Alfonso Jurado-Roman, MD, PhD; Santiago Jiménez-Valero, MD, PhD; Ariana Gonzálvez-García MD; Raul Moreno, MD, PhD

Borja Rivero-Santana, MD; Guillermo G...

Video Supplement to "Successful Valve-in-Valve Replacement Using Intravascular Lithotripsy for Femoral Access in an Elderly Patient With Critical Aortic Stenosis and Extensive Vascular Calcification" (Clinical Image).

Video Supplement to "Successful...

05/20/2024

Journal of Invasive Cardiology

Breaking Down Health Care

The Bear: Why Does Health Care Cost So Much? (Part 2)

05/20/2024

Michael Kolodziej , MD;

In part two of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into the other main stakeholders in health care costs: pharmaceutical manufacturers and providers. They discuss how these...

In part two of this two-part...

05/20/2024

Cancer Care Business Exchange

Conference Coverage

PD-1 Inhibitors for First-Line Treatment of Patients With Gastroesophageal Cancers

05/18/2024

Ryan Moy, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Ryan Moy, MD, PhD, discussed first-line use of PD-1 inhibitors for the treatment of patients with gastroesophageal cancers.

At Great Debates and Updates in...

05/18/2024

Oncology

Conference Coverage

Claudin-18.2 Inhibitors for First-Line Treatment of Patients With Gastroesophageal Cancer

05/18/2024

Samuel Cytryn, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Samuel Cytryn, MD, discussed first-line use of claudin-18.2 inhibitors for patients with gastroesophageal cancers.

At Great Debates and Updates in...

05/18/2024

Oncology

Videos

Balancing the Benefits and Risks of Value-Based Care Arrangements

05/16/2024

Lalan Wilfong , MD;

Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.

Lalan Wilfong, MD, discusses his...

05/16/2024

Journal of Clinical Pathways

Videos

The Facts You Need to Know About CTP Reimbursement

05/16/2024

Kathleen D. Schaum , MS;

Given the increased number of audits of those frequently using CTPs, and the recent release of proposed LCDs and LCAs on using CTPs for DFUs and VLUs, this SAWC Spring speaker discusses 10 major facts about CTP reimbursement.

Given the increased number of...

05/16/2024

Today's Wound Clinic

Conference Coverage

Should Docetaxel Plus Ramucirumab Be the Standard Second-Line Option for Patients With Non-Small Cell Lung Cancer?

05/15/2024

Edward Garon, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.

At the Great Debates and Updates...

05/15/2024

Oncology